US EditionNovo Nordisk Wants FDA Nod For A Higher-Dose Wegovy - Novo Nordisk (NYSE:NVO)
Novo Nordisk’s higher-dose Wegovy showed 20.7% average weight loss in a 72-week trial and is under expedited FDA review with a decision expected within 1-2 months.
9 Articles
9 Articles
The title took 4.67% at 314 kronor at 3:00 p.m. local (2:00 p.m. GMT), rising for the second consecutive session.
Novo Nordisk has applied to the US authorities for approval of a higher dose of the weight loss drug Wegovy. The Danish pharmaceutical company wrote in a press release on Wednesday. The US authorities have...
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy - Novo Nordisk (NYSE:NVO)
On Wednesday, Novo Nordisk A/S (NYSE:NVO) submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg for chronic weight management. NVO is among today's top performers. See the trading setup here The new, higher dose of Wegovy (semaglutide 7.2 mg) is currently under review with the European Medicines Agency, in the U.K., and several other countries. In the EU…
Novo Nordisk files for FDA approval of a higher dose of Wegovy injection 7.2 mg
Novo Nordisk announced the submission of a sNDA to the FDA for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity. Under the CNPV expedited program, review is expected within 1–2 months following the FDA's acceptance of the filing.The sNDA includes results from STEP UP, a 72-week phase 3, randomised, double-blind, placebo…
Coverage Details
Bias Distribution
- 40% of the sources are Center, 40% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
